AstraZeneca Finance plans to price fixed-rate notes in four parts

By Marisa Wong

Los Angeles, Feb. 21 – AstraZeneca Finance LLC is offering fixed-rate notes in four tranches, according to a 424B2 filing with the Securities and Exchange Commission.

The notes will be guaranteed by AstraZeneca plc.

Each of the tranches will feature a make-whole call option, followed by a par call option.

Barclays, Citigroup Global Markets Inc., Deutsche Bank Securities Inc. and J.P. Morgan Securities LLC are the joint bookrunners.

Bank of New York Mellon is the trustee.

Freshfields Bruckhaus Deringer US LLP, acting as the issuer’s U.S. counsel, will handle matters pertaining to U.S. federal law and New York state law, and Freshfields Bruckhaus Deringer LLP will deal with matters of English law for the issuer. Simpson Thacher & Bartlett LLP will handle U.S. legal matters for the underwriters.

Proceeds will be used for general corporate purposes, which may include the refinancing of existing debt, including outstanding debt under bank facilities.

AstraZeneca is a Cambridge, U.K.-based pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.